With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Morningstar8d
Regeneron's earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Mounjaro and Zepbound as treatments for obesity or diabetes. Regeneron is developing antibodies that may prevent that side effect, which is of particular concern for older patients. The Phase 2 ...
pharmaphorum1d
Regeneron and Alnylam seek RNAi therapies for NASH
Regeneron and Alnylam are to research treatments ... and is associated with increased risk of problems such as diabetes, heart attacks, and strokes. Drugs that get to market could generate ...
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’
We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks ...
Nasdaq3d
Regeneron Reports Positive Three-Year Results for EYLEA HD Treatment in Wet Age-Related Macular Degeneration
Regeneron Pharmaceuticals announced positive ... in the retina often caused by poor blood sugar control in people with diabetes. The disease generally starts as nonproliferative diabetic ...
Long Island Press15d
Four Nassau students named Regeneron finalists
Forty high school students, including four from Nassau County, have been selected as finalists for the annual Regeneron Science Talent Search.